Kearns-Sayre syndrome

Kearns-Sayre syndrome is a condition that affects many parts of the body, especially the eyes. The features of Kearns-Sayre syndrome usually appear before age 20, and the condition is diagnosed by a few characteristic signs and symptoms. People with Kearns-Sayre syndrome have progressive external ophthalmoplegia, which is weakness or paralysis of the eye muscles that impairs eye movement and causes drooping eyelids (ptosis). Affected individuals also have an eye condition called pigmentary retinopathy, which results from breakdown (degeneration) of the light-sensing tissue at the back of the eye (the retina) that gives it a speckled and streaked appearance. The retinopathy may cause loss of vision. In addition, people with Kearns-Sayre syndrome have at least one of the following signs or symptoms: abnormalities of the electrical signals that control the heartbeat (cardiac conduction defects), problems with coordination and balance that cause unsteadiness while walking (ataxia), or abnormally high levels of protein in the fluid that surrounds and protects the brain and spinal cord (the cerebrospinal fluid or CSF).

People with Kearns-Sayre syndrome may also experience muscle weakness in their limbs, deafness, kidney problems, or a deterioration of cognitive functions (dementia). Affected individuals often have short stature. In addition, diabetes mellitus is occasionally seen in people with Kearns-Sayre syndrome.

When the muscle cells of affected individuals are stained and viewed under a microscope, these cells usually appear abnormal. The abnormal muscle cells contain an excess of structures called mitochondria and are known as ragged-red fibers.

A related condition called ophthalmoplegia-plus may be diagnosed if an individual has many of the signs and symptoms of Kearns-Sayre syndrome but not all the criteria are met.

Frequency

The prevalence of Kearns-Sayre syndrome is approximately 1 to 3 per 100,000 individuals.

Genetic Changes

Kearns-Sayre syndrome is a condition caused by defects in mitochondria, which are structures within cells that use oxygen to convert the energy from food into a form cells can use. This process is called oxidative phosphorylation. Although most DNA is packaged in chromosomes within the nucleus (nuclear DNA), mitochondria also have a small amount of their own DNA, called mitochondrial DNA (mtDNA). This type of DNA contains many genes essential for normal mitochondrial function. People with Kearns-Sayre syndrome have a single, large deletion of mtDNA, ranging from 1,000 to 10,000
DNA building blocks (nucleotides). The cause of the deletion in affected individuals is unknown.

The mtDNA deletions that cause Kearns-Sayre syndrome result in the loss of genes important for mitochondrial protein formation and oxidative phosphorylation. The most common deletion removes 4,997 nucleotides, which includes twelve mitochondrial genes. Deletions of mtDNA result in impairment of oxidative phosphorylation and a decrease in cellular energy production. Regardless of which genes are deleted, all steps of oxidative phosphorylation are affected. Researchers have not determined how these deletions lead to the specific signs and symptoms of Kearns-Sayre syndrome, although the features of the condition are probably related to a lack of cellular energy. It has been suggested that eyes are commonly affected by mitochondrial defects because they are especially dependent on mitochondria for energy.

Inheritance Pattern

This condition is generally not inherited but arises from mutations in the body's cells that occur after conception. This alteration is called a somatic mutation and is present only in certain cells.

Rarely, this condition is inherited in a mitochondrial pattern, which is also known as maternal inheritance. This pattern of inheritance applies to genes contained in mtDNA. Because egg cells, but not sperm cells, contribute mitochondria to the developing embryo, children can only inherit disorders resulting from mtDNA mutations from their mother. These disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass traits associated with changes in mtDNA to their children.

Other Names for This Condition

- Kearns-Sayre mitochondrial cytopathy
- KSS

Diagnosis & Management

Genetic Testing

- Genetic Testing Registry: Kearns Sayre syndrome

Other Diagnosis and Management Resources

- GeneReview: Mitochondrial DNA Deletion Syndromes
  https://www.ncbi.nlm.nih.gov/books/NBK1203
- National Organization for Rare Disorders (NORD) Physician Guide: Mitochondrial Myopathies
  https://rarediseases.org/physician-guide/mitochondrial-myopathy/
General Information from MedlinePlus

- Diagnostic Tests
  https://medlineplus.gov/diagnostictests.html
- Drug Therapy
  https://medlineplus.gov/drugtherapy.html
- Genetic Counseling
  https://medlineplus.gov/geneticcounseling.html
- Palliative Care
  https://medlineplus.gov/palliativecare.html
- Surgery and Rehabilitation
  https://medlineplus.gov/surgeryandrehabilitation.html

Additional Information & Resources

MedlinePlus

- Encyclopedia: Cerebral Spinal Fluid Collection
  https://medlineplus.gov/ency/article/003428.htm
- Health Topic: Eye Diseases
  https://medlineplus.gov/eyediseases.html
- Health Topic: Heart Diseases
  https://medlineplus.gov/heartdiseases.html
- Health Topic: Retinal Disorders
  https://medlineplus.gov/retinaldisorders.html

Genetic and Rare Diseases Information Center

- Kearns-Sayre syndrome

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Kearns-Sayre Syndrome
  https://www.ninds.nih.gov/Disorders/All-Disorders/Kearns-Sayre-Syndrome-Information-Page
- National Institute of Neurological Disorders and Stroke: Mitochondrial Myopathies
  https://www.ninds.nih.gov/Disorders/All-Disorders/Mitochondrial-myopathy-Information-Page
- National Institutes of Health Rare Diseases Clinical Research Network: North American Mitochondrial Disease Consortium
  https://www.rarediseasesnetwork.org/cms/NAMDC
Educational Resources

• Cleveland Clinic Online Health Chats: Understanding Mitochondrial Disorders
  https://my.clevelandclinic.org/health/transcripts/parikh_understanding_mitochondrial_disorders

• Disease InfoSearch: Kearns-Sayre Syndrome
  http://www.diseaseinfosearch.org/Kearns-Sayre+Syndrome/3967

• MalaCards: kearns-sayre syndrome
  http://www.malacards.org/card/kearns_sayre_syndrome

• Mayo Clinic: Mitochondrial Disease Biobank
  http://www.mayo.edu/research/centers-programs/mitochondrial-disease-biobank/overview

• Muscular Dystrophy Association: Facts About Mitochondrial Myopathies

• Orphanet: Kearns-Sayre syndrome
  http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=480

• United Mitochondrial Disease Foundation: Types of Mitochondrial Disease
  http://www.umdf.org/types/

• United Mitochondrial Disease Foundation: What is Mitochondrial Disease?
  http://www.umdf.org/what-is-mitochondrial-disease/

• University of Iowa: Chronic Progressive External Ophthalmoplegia - Kearns-Sayre Syndrome
  http://webeye.ophth.uiowa.edu/eyeforum/cases/case24.htm

• University of Virginia Health System: Myopathy
  https://neurosciences.uvahealth.com/services/als-neuromuscular-disease/myopathy

Patient Support and Advocacy Resources

• MitoAction
  http://www.mitoaction.org/

• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/kearns-sayre-syndrome/

• United Mitochondrial Disease Foundation
  http://www.umdf.org/

GeneReviews

• Mitochondrial DNA Deletion Syndromes
  https://www.ncbi.nlm.nih.gov/books/NBK1203
ClinicalTrials.gov
- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=r22Kearns-Sayre+syndrome+r22+OR+
  r22Mitochondrial+Ocular+Myopathies+r22+OR+r22External+Ophthalmoplegia
  r22+C+Progressive+r22

Scientific Articles on PubMed
- PubMed
  r5BMAJR%s29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+
  r22last+r1800+days%22%5Bdp%5D

OMIM
- KEARNS-SAYRE SYNDROME
  http://omim.org/entry/530000

Sources for This Summary
- DiMauro S, Hirano M. Mitochondrial DNA Deletion Syndromes. 2003 Dec 17 [updated 2011 May 3].
  In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N,
  Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301382

- Graeber MB, Müller U. Recent developments in the molecular genetics of mitochondrial disorders. J
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9511882

- Porteous WK, James AM, Sheard PW, Porteous CM, Packer MA, Hyslop SJ, Melton JV, Pang
  CY, Wei YH, Murphy MP. Bioenergetic consequences of accumulating the common 4977-bp
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9799119

- Schröder R, Vielhaber S, Wiedemann FR, Kornblum C, Papassotiropoulos A, Broich P,
  Zierz S, Elger CE, Reichmann H, Seibel P, Klockgether T, Kunz WS. New insights into the
  metabolic consequences of large-scale mtDNA deletions: a quantitative analysis of biochemical,
  May;59(5):353-60.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1088364

- Sciacco M, Bonilla E, Schon EA, DiMauro S, Moraes CT. Distribution of wild-type and common
  deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with
  Apr;3(4):687.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8162014

- Yamashita S, Nishino I, Nonaka I, Goto Y. Genotype and phenotype analyses in 136 patients with
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18414780